Fig. 3.

OICR-9429 increases apoptosis and chemosensitivity of bladder cancer cells. a. Apoptosis analysis of three BCa cell lines treated with two OICR-9429 doses or DMSO for 24, 48, and 72 h. The histogram shows the percentage (%) of apoptotic cells. b. Three BCa cells were treated with various concentrations of cisplatin combined with three concentrations of OICR-9429 (0, IC₅₀, 2 IC₅₀) for 72 h. Cell viability was determined by MTT assay. c. d. The comet assay (c) and histogram (d) analysis of three BCa cells treated with 2 IC₅₀ OICR-9429, cisplatin (2 μg/mL), and a combined treatment with IC₅₀ OICR-9429 and low-dose cisplatin (1 μg/mL) for 48 h. e. The apoptosis analysis of two BCa cells treated with 2 concentrations of OICR-9429 (IC₅₀, 2 IC₅₀), 2 concentrations of cisplatin (1, 2 μg/mL), and a combined treatment with IC₅₀ OICR-9429 and low-dose cisplatin (1 μg/mL) for 72 h. f. The histogram showed the percentage (%) of apoptotic cells. *p < 0.05 and **p < 0.01